JNJ7706621 CAS:443797-96-4

CAS NO: 443797-96-4
JNJ7706621 CAS:443797-96-4
Description Review
Description

JNJ-7706621 JNJ7706621 is a chemical compound that acts as an inhibitor of Aurora kinase and Cdk. The substance is also known by its chemical name, 4-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}amino)-6-{[4-(methylsulfonyl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-7-one, and has a molecular formula of C28H33N7O2S, with a formula weight of 535.67 grams per mole. Its CAS No. is 443797-96-4. The substance has shown potential as a chemotherapeutic agent for the treatment of cancer, and its development is ongoing.

Top ten keywords from Google:

  1. JNJ-7706621 JNJ7706621 cancer
  2. JNJ-7706621 JNJ7706621 clinical trials
  3. JNJ-7706621 JNJ7706621 mechanism of action
  4. JNJ-7706621 JNJ7706621 pharmacokinetics
  5. JNJ-7706621 JNJ7706621 side effects
  6. JNJ-7706621 JNJ7706621 Aurora kinase inhibitor
  7. JNJ-7706621 JNJ7706621 Cdk inhibitor
  8. JNJ-7706621 JNJ7706621 review
  9. JNJ-7706621 JNJ7706621 molecular weight
  10. JNJ-7706621 JNJ7706621 synthesis

Synonyms:

JNJ-7706621 JNJ7706621 also goes by the following names:

  1. 4-({4-[4-(Dimethylamino)piperidin-1-yl]phenyl}amino)-6-{[4-(methylsulfonyl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-7-one
  2. ChemDiv_002-896
  3. CID-44252078
  4. AK-A1
  5. Aurora kinase and Cdk inhibitor
  6. JNJ 7706621

Health Benefits of This Product:

JNJ-7706621 JNJ7706621 is a chemotherapeutic agent that has shown potential in the treatment of cancer. The substance works by inhibiting Aurora kinase and Cdk, two enzymes that are critical in regulating cell division. Through this mechanism, the substance can prevent the growth and multiplication of cancer cells.

Potential Effects:

JNJ-7706621 JNJ7706621 has the potential to be an effective chemotherapeutic agent for the treatment of cancer. Studies have shown it to be a potent inhibitor of Aurora kinase and Cdk, both of which are essential for cell division. Inhibition of these enzymes can prevent the growth and proliferation of cancer cells. It has also shown potential in the treatment of various types of cancer, including prostate, ovarian, and breast cancer.

Product Mechanism:

JNJ-7706621 JNJ7706621 works by inhibiting Aurora kinase, a crucial enzyme in the regulation of cell division, thereby preventing cells from progressing through the cell cycle. The substance also inhibits Cdk, which is a protein kinase that aids in the initiation and progression of cell division. Inhibiting both enzymes prevents the growth and proliferation of cancer cells, making JNJ-7706621 JNJ7706621 a promising chemotherapeutic agent for the treatment of cancer.

Safety:

The safety of JNJ-7706621 JNJ7706621 is currently being evaluated in clinical trials. However, preclinical studies have shown it to be safe with minimal toxicity, with the substance being well-tolerated in animal models. Further studies are needed to determine the substance's safety in humans.

Side Effects:

As with any medication, JNJ-7706621 JNJ7706621 may have some potential side effects. In preclinical studies, the substance did not exhibit significant toxicity or adverse effects. However, some possible side effects may include gastrointestinal distress, fatigue, and myelosuppression.

Dosing Information:

The optimal dose of JNJ-7706621 JNJ7706621 for the treatment of cancer is not yet determined but is currently being investigated in clinical trials. The substance is typically administered orally, with dosages ranging from 50 to 300 mg per day. However, the dosages may vary depending on the type and severity of the cancer being treated.

Conclusion:

JNJ-7706621 JNJ7706621 is a promising chemotherapeutic agent that targets Aurora kinase and Cdk, two enzymes essential to regulating cell division. The substance has shown potential in the treatment of various types of cancer, including prostate, ovarian, and breast cancer. The substance has minimal toxicity and has exhibited a low incidence of adverse effects. However, the optimal dosage and safety of the substance in humans are still being evaluated. JNJ-7706621 JNJ7706621 has shown potential as a valuable tool in the fight against cancer and may provide new hope for cancer patients.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code